The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.
SCAI has shared a new call to action as an observance of American Heart Month. The group is asking Congress to pass new pieces of legislation that could improve care for PAD patients and get important medical devices in the hands of interventional cardiologists.
The Magnolia, Texas, firm has seen rapid growth in recent years, being named to the Deloitte Technology Fast 500 in 2024 after logging revenue growth of 212% over a three-year period.
Sens. Tim Kaine, D-Va., and John Boozman, R-Ark., have introduced legislation to lift "arbitrary" caps on compensation for therapeutic and diagnostic medical physicists working in the VA.
Siemens self-reported a problem with software being inadvertently delivered to U.S. systems when the applications have not yet been cleared for use by the FDA.
The U.S. Food and Drug Administration has its hands full making sure medical AI products are safe, efficacious and trustworthy before they hit the market. The rise of ever-more-innovative iterations of the technology—not least generative AI—is only adding to the burden.
Device-based therapies can provide considerable value for heart failure patients when used alongside traditional pharmaceutical treatments. A new HFSA scientific statement outlines the benefits of these devices, urging care teams to implement them into daily practice.
The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.
